Skip to main content
. 2020 Oct 24;396(10259):1345–1352. doi: 10.1016/S0140-6736(20)32013-4

Figure 1.

Figure 1

Trial profile

*Number recruited overall during the period that participants could be recruited into lopinavir–ritonavir comparison. †Some patients were included in both of the below groups. ‡A second randomisation to tocilizumab versus usual care in patients with hypoxia and C-reactive protein ≥75 mg/L was introduced in protocol version 4.0.